Olanzapine for young PEople with aNorexia nervosa (OPEN): results of a feasibility study.

ABSTRACT:

Background

Despite the availability of evidence-based treatments for anorexia nervosa (AN), remission rates are moderate, and mortality is high. Olanzapine is used as adjunct therapy for AN in case of insufficient response to first-line treatments, even though the evidence is limited. Its effect on eating disorder (ED) psychopathology, its efficacy and tolerability, and its acceptability and adherence rate are unclear.

Methods

We assessed the feasibility of a future definitive trial on olanzapine in young people with AN in an open-label, one-armed feasibility study that aimed to include 55 patients with AN or atypical AN aged 12-24 who gained < 2 kg within at least one month of treatment as usual (TAU) during outpatient, inpatient, or day-care treatment. Time points for asse

SUBMITTER: Said O 

PROVIDER: S-EPMC11542358 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature